Small molecule · Inhibitor of protein arginine methyltransferase 5 (PRMT5) · developed by Tango Therapeutics
Ralometostat is an orally available small molecule that selectively binds and inhibits PRMT5, a methyltransferase that catalyzes arginine methylation of histones and other proteins. It is being studied in locally advanced solid tumors, with MTAP-deleted cancer cells showing particular sensitivity to PRMT5 inhibition.
Summary written with AI from the sources listed at the end of this page.
| Trial | Phase | Condition | Status | Sponsor |
|---|---|---|---|---|
| NCT05275478 | Phase 1/2 | Locally Advanced Solid Tumor | Terminated | TNGX |
Trials of the companies BioRadar tracks, from ClinicalTrials.gov, most advanced phase first.
Locally Advanced Solid Tumor
Updated Nov 1, 2026. Something wrong or missing? Report it on the TNGX page.
See TNGX's upcoming FDA decisions, trial readouts, cash runway and dilution risk, updated every day from SEC, FDA and ClinicalTrials.gov filings.
TNGX catalysts and pipeline →